Exopolysaccharide from Lactobacillus rhamnosus ZFM231 alleviates DSS-induced colitis in mice by regulating gut microbiota.
- 2022-07-02
- Journal of the Science of Food and Agriculture 102(15)
- C. Wan
- Wen-Wen Qian
- W. Liu
- X. Pi
- Meng Tang
- Xiao-Lin Wang
- Q. Gu
- Ping Li
- Tao Zhou
- PubMed: 35707876
- DOI: 10.1002/jsfa.12070
Abstract
Background: The exopolysaccharides (EPS) produced by Lactobacillus and other probiotics are associated with many benefits, such as immune regulation, antioxidant properties, antitumor effect, and regulation of intestinal microbe homeostasis. In the present study, the modulatory effect of EPS produced by Lactobacillus rhamnosus ZFM231 on the intestinal flora of mice with inflammatory bowel disease induced by dextran sulfate solution was investigated.
Results: Results indicated that weight loss, colonic length, the disease activity index score and colonic tissue damage in mice were significantly improved by EPS treatment. Compared with the model group, in the EPS-treated group, the diversity of and the composition of gut microbiota at both phylum and genus levels were found to recover to the levels of normal group, indicating the effective modulation on gut microbiota by EPS; short-chain fatty acids, including acetic acid, propionic acid and butyric acid produced by intestinal microbial metabolism, increased significantly; the level of anti-inflammatory factor transforning growth factor-β significantly increased and the level of pro-inflammatory factor tumor necrosis factor-α significantly decreased in the colonic cells of EPS-treated mice.
Conclusion: It is clear that EPS produced by L. rhamnosus ZFM231 could find application in functional foods with the property of anti-ulcerative colitis. The experimental results provide new insights into the probiotic effect of EPS. © 2022 Society of Chemical Industry.
Keywords: DSS-induced colitis; Lactobacillus rhamnosus; exopolysaccharide; gut microbiota; short-chain fatty acid.
Research Insights
| Supplement | Health Outcome | Effect Type | Effect Size |
|---|---|---|---|
| Lactobacillus rhamnosus | Improved Colonic Length | Beneficial | Moderate |
| Lactobacillus rhamnosus | Improved Gut Microbiota Diversity | Beneficial | Large |
| Lactobacillus rhamnosus | Increased Anti-Inflammatory Factor (TGF-β) | Beneficial | Moderate |
| Lactobacillus rhamnosus | Increased Short-Chain Fatty Acid Levels | Beneficial | Moderate |
| Lactobacillus rhamnosus | Reduced Body Weight | Beneficial | Moderate |
| Lactobacillus rhamnosus | Reduced Disease Activity Score | Beneficial | Moderate |
| Lactobacillus rhamnosus | Reduced Pro-Inflammatory Factor TNF-α | Beneficial | Large |
| Lactobacillus rhamnosus | Reduced Tissue Damage from Colitis | Beneficial | Moderate |
| Lactobacillus rhamnosus DSM33560 | Improved Colonic Health | Beneficial | Moderate |
| Lactobacillus rhamnosus DSM33560 | Increased Short-Chain Fatty Acid Production | Beneficial | Moderate |
| Lactobacillus rhamnosus DSM33560 | Reduced Body Weight Loss | Beneficial | Moderate |
| Lactobacillus rhamnosus DSM33560 | Reduced Inflammation Levels | Beneficial | Large |
| Lactobacillus rhamnosus DSM33560 | Restored Microbial Diversity | Beneficial | Large |
| Lactobacillus rhamnosus lysate powder | Improved Colonic Length | Beneficial | Moderate |
| Lactobacillus rhamnosus lysate powder | Improved Disease Activity Index Score | Beneficial | Moderate |
| Lactobacillus rhamnosus lysate powder | Improved Gut Microbiota Diversity | Beneficial | Large |
| Lactobacillus rhamnosus lysate powder | Increased Anti-Inflammatory Factor (TGF-β) | Beneficial | Moderate |
| Lactobacillus rhamnosus lysate powder | Increased Short-Chain Fatty Acid Levels | Beneficial | Moderate |
| Lactobacillus rhamnosus lysate powder | Reduced Body Weight | Beneficial | Moderate |
| Lactobacillus rhamnosus lysate powder | Reduced Tissue Damage from Colitis | Beneficial | Moderate |
| Lactobacillus rhamnosus lysate powder | Reduced Tumor Necrosis Factor Alpha | Beneficial | Moderate |